PXB17
PXB17 can inhibit CSF1R (IC50 = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC[1].
Product Specifications
UNSPSC
12352005
Target
C-Fms
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pxb17.html
Solubility
10 mM in DMSO
Smiles
CC1=C(C(C)=C(N1)/C=C2C(NC3=C\2C=CC(NC(NC4=NOC(C(C)(C)C)=C4)=O)=C3)=O)NC(CN5CCCC5)=O
Molecular Formula
C29H35N7O4
Molecular Weight
545.63
References & Citations
[1]Qi L et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer Pharmacological Research 202 (2024) 107126.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSQ050105-01 10 µg
Recombinant Cynomolgus Signal-Regulatory Protein alpha-1/SIRPA/CD172a (C-6His)
Sign In for Pricing
View Details PKSQ050105-02 50 µg
Recombinant Cynomolgus Signal-Regulatory Protein alpha-1/SIRPA/CD172a (C-6His)
Sign In for Pricing
View Details 